tert-butyl 4-((3-bromo-2-chloropyridin-4-ylamino)methyl)-5,6-dihydropyridine-1(2H)-carboxylate | 857730-22-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: tert-butyl 4-((3-bromo-2-chloropyridin-4-ylamino)methyl)-5,6-dihydropyridine-1(2H)-carboxylate
• 英文别名: 4-[(3-bromo-2-chloro-pyridin-4-ylamino)-methyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester；4-[(3-Bromo-2-chloro-pyridin-4-ylamino)-methyl]-3,6-dihydro-2H-pyridine-1-carboxylic acid tert-butyl ester；tert-butyl 4-[[(3-bromo-2-chloropyridin-4-yl)amino]methyl]-3,6-dihydro-2H-pyridine-1-carboxylate
• CAS: 857730-22-4
• 化学式: C₁₆H₂₁BrClN₃O₂
• 分子量: 402.719
• InChiKey: FXVMHULTOXVPSY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  23
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  54.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((3-bromo-2-chloropyridin-4-ylamino)methyl)-5,6-dihydropyridine-1(2H)-carboxylate 在 4-二甲氨基吡啶 、 四丁基溴化铵 、 palladium diacetate 、 三乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基乙酰胺 为溶剂， 反应 24.0h， 生成 tert-butyl 4'-chloro-1',2,2',3-tetrahydro-1H-spiro[pyridine-4,3'-pyrrolo[3,2-c]pyridine]-1-carboxylate
  参考文献：
  名称：

  Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y₁ Antagonist

  摘要：

  Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y(1) antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y(12) antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y(1) antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 31 will also be presented. Compound 31 was our first P2Y(1) antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

  DOI：

  10.1021/jm4013906
• 作为产物：
  描述：

  N-Boc-4-(羟甲基)-1,2,3,6-四氢吡啶 在 2,6-二甲基吡啶 、 氯化亚砜 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 为溶剂， 反应 41.0h， 生成 tert-butyl 4-((3-bromo-2-chloropyridin-4-ylamino)methyl)-5,6-dihydropyridine-1(2H)-carboxylate
  参考文献：
  名称：

  Conformationally Constrained ortho-Anilino Diaryl Ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y₁ Antagonist

  摘要：

  Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y(1) antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y(12) antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y(1) antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 31 will also be presented. Compound 31 was our first P2Y(1) antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.

  DOI：

  10.1021/jm4013906

文献信息

• [EN] SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS<br/>[FR] DÉRIVÉS DE SPIROPIPÉRIDINE POUR LUTTER CONTRE LES NUISIBLES
  申请人：SYNGENTA PARTICIPATIONS AG

  公开号：WO2005061500A1

  公开（公告）日：2005-07-07

  The use of a compound of Formula (I), Y is a single bond, C=O, C=S or S(O)m where m is 0, 1 or 2; the ring represented by T is a 5 or 6 membered heteroaromatic and R1, R2, R3, R8 and Ra are specified organic groups and p is 0, 1, 2, 3, 4, 5 or 6; p+q is 1, 2, 3, 4, 5 or 6; or salts or N-oxides thereof or compositions containing them in controlling insects, acarines, nematodes or molluscs; novel compounds are also provided.

  使用Formula（I）中的化合物，其中Y是单键，C=O，C=S或S（O）m，其中m为0、1或2；T表示的环是5或6个成员的杂芳族，R1、R2、R3、R8和Ra是指定的有机基团，p为0、1、2、3、4、5或6；p+q为1、2、3、4、5或6；或其盐或N-氧化物或含有它们的组合物在控制昆虫、螨虫、线虫或软体动物方面；还提供了新化合物。
• Spiropiperidine derivatives for controlling pests
  申请人：Cassayre Jerome

  公开号：US20070135408A1

  公开（公告）日：2007-06-14

  The use of a compound of Formula (I), Y is a single bond, C═O, C═S or S(O)m where m is 0, 1 or 2; the ring represented by T is a 5 or 6 membered heteroaromatic and R 1 , R 2 , R 3 , R 8 and Ra are specified organic groups and p is 0, 1, 2, 3, 4, 5 or 6; p+q is 1, 2, 3, 4, 5 or 6; or salts or N-oxides thereof or compositions containing them in controlling insects, acarines, nematodes or molluscs; novel compounds are also provided.

  使用式（I）化合物，其中Y为单键，C═O，C═S或S（O）m，其中m为0、1或2；所表示的环T为5或6成员的杂环芳香族，并且R1、R2、R3、R8和Ra是指定的有机基团，p为0、1、2、3、4、5或6；p+q为1、2、3、4、5或6；或其盐或N-氧化物或含有它们的组合物，在控制昆虫、螨、线虫或软体动物方面提供了新的化合物。
• SPIROPIPERIDINE DERIVATIVES FOR CONTROLLING PESTS
  申请人：Syngenta Participations AG

  公开号：EP1694677A1

  公开（公告）日：2006-08-30
• US7960401B2
  申请人：——

  公开号：US7960401B2

  公开（公告）日：2011-06-14
• Conformationally Constrained <i>ortho-</i>Anilino Diaryl Ureas: Discovery of 1-(2-(1′-Neopentylspiro[indoline-3,4′-piperidine]-1-yl)phenyl)-3-(4-(trifluoromethoxy)phenyl)urea, a Potent, Selective, and Bioavailable P2Y₁ Antagonist
  作者：Jennifer X. Qiao、Tammy C. Wang、Réjean Ruel、Carl Thibeault、Alexandre L’Heureux、William A. Schumacher、Steven A. Spronk、Sheldon Hiebert、Gilles Bouthillier、John Lloyd、Zulan Pi、Dora M. Schnur、Lynn M. Abell、Ji Hua、Laura A. Price、Eddie Liu、Qimin Wu、Thomas E. Steinbacher、Jeffrey S. Bostwick、Ming Chang、Joanna Zheng、Qi Gao、Baoqing Ma、Patricia A. McDonnell、Christine S. Huang、Robert Rehfuss、Ruth R. Wexler、Patrick Y. S. Lam

  DOI：10.1021/jm4013906

  日期：2013.11.27

  Preclinical antithrombotic efficacy and bleeding models have demonstrated that P2Y(1) antagonists are efficacious as antiplatelet agents and may offer a safety advantage over P2Y(12) antagonists in terms of reduced bleeding liabilities. In this article, we describe the structural modification of the tert-butyl phenoxy portion of lead compound 1 and the subsequent discovery of a novel series of conformationally constrained ortho-anilino diaryl ureas. In particular, spiropiperidine indoline-substituted diaryl ureas are described as potent, orally bioavailable small-molecule P2Y(1) antagonists with improved activity in functional assays and improved oral bioavailability in rats. Homology modeling and rat PK/PD studies on benchmark compound 31 will also be presented. Compound 31 was our first P2Y(1) antagonist to demonstrate a robust oral antithrombotic effect with mild bleeding liability in the rat thrombosis and hemostasis models.